• Mariusz Piechota, Marcin Barylski, Simon Hannam, Magdalena Piechota-Urbańska, and Maciej Banach.
• Department of Anesthesiology and Intensive Therapy, Military Medical Academy University Hospital in Lodz, Hallera Sq 1, 90-647 Lodz, Poland. mariuszpiechota@poczta.onet.pl.
• Curr Vasc Pharmacol. 2013 Sep 1;11(5):795-800.

AbstractStatins are well-established and effective drugs in the treatment of hyperlipidemias. However the effects of statins extend beyond lipid-lowering. The pleiotropic effects of statins have been shown to modify inflammatory cell signaling of the immune response to infection. Statins have emerged as potential immunomodulatory and antioxidant agents that might impact on sepsis outcomes. It was postulated that statins may be candidates for the treatment of sepsis. Recent animal and human data suggest that statin therapy might be beneficial in patients before the onset of sepsis or in its initial period, but should be used with care when patients are diagnosed with severe sepsis or septic shock. Some analyses also provide evidence for statins as an adjuvant therapy in sepsis. Because of the divergent results of studies, the potential benefit needs to be validated in randomized, controlled trials. In this review, we describe current evidence on the use of statins in the prevention and treatment of sepsis.

9 keywords...

hide…